Phase II Results of the GEOMETRY Mono-1 Study in NSCLC

Juergen Wolf, MD

Juergen Wolf, MD, medical director, Center for Integrated Oncology (CIO) at the University Hospital Cologne, discusses the phase II findings of the GEOMETRY mono-1 study in patients with MET exon 14-mutated advanced non-small cell lung cancer.

Juergen Wolf, MD, medical director, Center for Integrated Oncology (CIO) at the University Hospital Cologne, discusses the phase II findings of the GEOMETRY mono-1 study in patients withMETexon 14-mutated advanced non-small cell lung cancer (NSCLC).

In findings from the GEOMETRY trial presented at the 2018 ESMO Congress, an overall response rate (ORR) of 72.0% was observed for the investigational MET inhibitor capmatinib (INC280) in treatment-naive patients and 39.1% in previously treated patients. The safety profile was tolerable, and results suggest that this agent may be beneficial to patients with exon 14 skipping mutations.

These first-line data are very exciting, Wolf says, as this ORR has never been reported in patients withMET